Striatal dopamine nerve terminal markers in human, chronic methamphetamine users
Nature Medicine1996Vol. 2(6), pp. 699–703
Citations Over TimeTop 10% of 1996 papers
Julie M. Wilson, Kathryn S. Kalasinsky, Allan I. Levey, Catherine Bergeron, Gregory D. Reiber, Robert M. Anthony, Gregory A. Schmunk, Kathleen Shannak, John W. Haycock, Stephen J. Kish
Related Papers
- → The vesicular monoamine transporter is not regulated by dopaminergic drug treatments(1995)206 cited
- → Acute exposure to aroclor 1016 or 1260 differentially affects dopamine transporter and vesicular monoamine transporter 2 levels(2004)100 cited
- → Region‐specific targeting of dopamine D2‐receptors and somatodendritic vesicular monoamine transporter 2 (VMAT2) within ventral tegmental area subdivisions(2002)47 cited
- → Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture(2007)20 cited
- → Coordinated expression of dopamine transporter and vesicular monoamine transporter in the primate striatum during development(2013)